Busemann Christoph, Klein Susanne, Schmidt Christian Andreas, Evert Matthias, Dölken Gottfried, Krüger William H
Department of Internal Medicine C (Haematology and Oncology, Marrow Transplantation), Ernst-Moritz-Arndt-University Greifswald, Ferdinand-Sauerbruch-Str., 17475 Greifswald, Germany.
Institute for Pathology, Ernst-Moritz-Arndt-University Greifswald, Ferdinand-Sauerbruch-Str., 17475 Greifswald, Germany.
Indian J Hematol Blood Transfus. 2015 Mar;31(1):14-20. doi: 10.1007/s12288-014-0398-9. Epub 2014 May 11.
Prognosis of peripheral and other advanced T cell lymphomas is poor. 20 patients with a median age of 46.4 (range 20.5-64.1) years were treated with autoSCT (n = 6) or alloSCT (n = 14) from 1996 to 2013. All patients were at high risk either due to the IPI-score or to the fact that SCT was part of a salvage therapy. Conditioning prior to alloSCT was myeloablative in seven cases (50 %). The patients were pretreated with 8.5 (median, range 2-38) cycles of chemotherapy. Ten patients are alive in CR after a median follow-up of 1.3 years (range 0.1-13.3). OS was 53 % after one and 40 % after 10 years. Best survival was reached after related alloSCT (80 % at 10 years) compared to other modalities. GvHD did not influence survival. AlloSCT from related donors can cure patients from T-cell lymphomas. Unrelated alloSCT or high-dose therapy and autoSCT are an option for patients without a familiar donor.
外周及其他晚期T细胞淋巴瘤的预后较差。1996年至2013年期间，20例患者接受了自体造血干细胞移植（n = 6）或异基因造血干细胞移植（n = 14），中位年龄为46.4岁（范围20.5 - 64.1岁）。所有患者均因国际预后指数（IPI）评分或因自体造血干细胞移植是挽救治疗的一部分而处于高风险状态。异基因造血干细胞移植前的预处理在7例患者中（50%）采用了清髓性方案。患者接受了8.5个（中位，范围2 - 38个）周期的化疗预处理。中位随访1.3年（范围0.1 - 13.3年）后，10例患者处于完全缓解（CR）状态存活。1年总生存率（OS）为53%，10年为40%。与其他治疗方式相比，亲属供者异基因造血干细胞移植后的生存率最佳（10年时为80%）。移植物抗宿主病（GvHD）不影响生存率。亲属供者的异基因造血干细胞移植可治愈T细胞淋巴瘤患者。对于没有合适亲属供者的患者，非亲属供者异基因造血干细胞移植或高剂量治疗及自体造血干细胞移植也是一种选择。
